127 related articles for article (PubMed ID: 38049966)
1. Primary Adenosquamous Carcinoma of the Prostate With Multiple Heterogenic Metastases Demonstrated on 68 Ga-PSMA and 18 F-FDG PET/CT Imaging.
Yang J; Xiao L; Gao X; Tang Y; Hu S
Clin Nucl Med; 2024 Feb; 49(2):180-181. PubMed ID: 38049966
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.
Nazar AK; Kalshetty A; Chakravarty R; Chakraborty S; Basu S
Nucl Med Commun; 2023 Oct; 44(10):910-923. PubMed ID: 37578310
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen-Avid Bone Metastases From Urothelial Carcinoma of the Bladder.
Zhao B; Dong A; Zuo C
Clin Nucl Med; 2022 Oct; 47(10):892-894. PubMed ID: 35439183
[TBL] [Abstract][Full Text] [Related]
5. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate.
Qiu S; Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Sep; 47(9):836-838. PubMed ID: 35439204
[TBL] [Abstract][Full Text] [Related]
6.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
7. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
8. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
Perez PM; Hope TA; Behr SC; van Zante A; Small EJ; Flavell RR
Clin Nucl Med; 2019 Jan; 44(1):e28-e32. PubMed ID: 30394930
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous uptake of
Hu Y; Wang P; Dai W
BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
[TBL] [Abstract][Full Text] [Related]
10. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract][Full Text] [Related]
11. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
12.
Qi Z; Yao X; Su M; Huang R
Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
[TBL] [Abstract][Full Text] [Related]
13. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
Pang Y; Meng T; Xu W; Shang Q; Chen H
Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
[TBL] [Abstract][Full Text] [Related]
14. Visualization of Intermetastatic Heterogeneity in Mixed Neuroendocrine Carcinoma-Acinar Adenocarcinoma of the Prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
Cai J; Xu W; Meng T; Pang Y; Chen H
Clin Nucl Med; 2023 Aug; 48(8):743-745. PubMed ID: 37220226
[TBL] [Abstract][Full Text] [Related]
15. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
Sutherland DEK; Azad AA; Murphy DG; Eapen RS; Kostos L; Hofman MS
Semin Nucl Med; 2024 Jan; 54(1):4-13. PubMed ID: 37400321
[TBL] [Abstract][Full Text] [Related]
17. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
18. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of 18 F-FDG PET/CT and 68 Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer.
Öztürk AE; Şahin R; Ergül N; Çermik TF; Arslan E
Clin Nucl Med; 2024 Feb; 49(2):e68-e69. PubMed ID: 38170920
[TBL] [Abstract][Full Text] [Related]
20.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
